Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Cholangiocarcinoma 1

Interventions

Decitabine 3decitabine and cedazuridine drug combination 2cedazuridine 2Cytarabine 2Azacitidine 2treosulfan 1olutasidenib 1luspatercept 1ivosidenib 1imetelstat 1glasdegib 1enasidenib 1GRN163L peptide 1Daunorubicin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Myelodysplastic Syndromes × ivosidenib × Clear all
NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Servier

Phase 1 Recruiting
291 enrolled 3 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡